Hikma Pharmaceuticals


23/03/20 -"While FY19 earnings benefited from a lower effective tax rate, we have trimmed our FY20 estimates slightly due to rising API costs across the globe. However, we maintain our positive stance on the ..."

Pages
47
Language
English
Published on
23/03/20
You may also be interested by these reports :
08/04/20
When we last pushed GlaxoSmithKline’s (GSK) (Add, UK) investment story in mid-2017, the newly-appointed CEO, Emma Walmsley (consumer health veteran), ...

07/04/20
Our target price moves marginally higher due to increases in the intrinsic valuations, which factor in better than expected performance in the face ...

27/03/20
Given that >50% of Faes Farma’s sales come from Spain, a region which is adversely affected with the ongoing COVID-19 crisis, we have slashed our ...

26/03/20
Well-positioned in the plasma industry, Grifols could be a winner from the ongoing pandemic crisis — as the Spanish pharma giant has joined forces ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO